Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers 13.11 (2021): 2594.
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2021
- Urheber
-
Zeuschner, Philip
Hölters, Sebastian
Stöckle, Michael
Seliger, Barbara
Mueller, Anja
Bachmann, Hagen S.
Grünwald, Viktor
Christoph, Daniel C.
Stenzl, Arnulf
Grimm, Marc-Oliver
Brüning, Fabian
Goebell, Peter Jürgen
Augustin, Marinela
Roos, Frederik
Harde, Johanna
Benz-Rüd, Iris
Staehler, Michael
Junker, Kerstin
- DOI
-
10.3390/cancers13112594
- URN
-
urn:nbn:de:bvb:29-opus4-165700
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zeuschner, Philip
- Hölters, Sebastian
- Stöckle, Michael
- Seliger, Barbara
- Mueller, Anja
- Bachmann, Hagen S.
- Grünwald, Viktor
- Christoph, Daniel C.
- Stenzl, Arnulf
- Grimm, Marc-Oliver
- Brüning, Fabian
- Goebell, Peter Jürgen
- Augustin, Marinela
- Roos, Frederik
- Harde, Johanna
- Benz-Rüd, Iris
- Staehler, Michael
- Junker, Kerstin
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2021
Ähnliche Objekte (12)
Thrombospondin-2 and LDH are putative predictive biomarkers for treatment with everolimus in second-line metastatic clear Ccll renal cell carcinoma (MARC-2 study)
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression
Role of Plasmodium falciparum thrombospondin-related anonymous protein in host-cell interactions
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells
Thrombospondin-1 protects against Aβ-induced mitochondrial fragmentation and dysfunction in hippocampal cells
Thrombospondin-2 and LDH are putative predictive biomarkers for treatment with everolimus in second-line metastatic clear Ccll renal cell carcinoma (MARC-2 study)
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression
Role of Plasmodium falciparum thrombospondin-related anonymous protein in host-cell interactions
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells
Thrombospondin-1 protects against Aβ-induced mitochondrial fragmentation and dysfunction in hippocampal cells
Thrombospondin-2 and LDH are putative predictive biomarkers for treatment with everolimus in second-line metastatic clear Ccll renal cell carcinoma (MARC-2 study)
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression
Role of Plasmodium falciparum thrombospondin-related anonymous protein in host-cell interactions
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells